Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Update

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 10,180,000 shares, an increase of 10.5% from the May 31st total of 9,210,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 8.0 days.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AUPH. Lazard Asset Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 138.0% in the 3rd quarter. Lazard Asset Management LLC now owns 55,428 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 32,137 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter worth about $2,089,000. DekaBank Deutsche Girozentrale boosted its position in Aurinia Pharmaceuticals by 125.9% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 19,088 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 10,640 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Aurinia Pharmaceuticals by 57.7% during the 4th quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock worth $85,729,000 after acquiring an additional 3,488,000 shares during the period. Finally, Hudson Bay Capital Management LP grew its holdings in shares of Aurinia Pharmaceuticals by 19.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 156,484 shares of the biotechnology company’s stock worth $1,216,000 after acquiring an additional 25,000 shares during the period. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 1.6 %

NASDAQ AUPH opened at $5.71 on Monday. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $12.43. The stock has a market capitalization of $814.59 million, a PE ratio of -13.28 and a beta of 1.44. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.60 and a quick ratio of 5.05. The business’s 50-day moving average is $5.33 and its 200 day moving average is $6.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.14. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. The firm had revenue of $50.30 million for the quarter, compared to analyst estimates of $46.30 million. Sell-side analysts forecast that Aurinia Pharmaceuticals will post 0.15 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.